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ABSTRACT In this study, we investigated the role of elevated sarcoplasmic reticulum (SR) Ca21 leak through ryanodine
receptors (RyR2s) in heart failure (HF)-related abnormalities of intracellular Ca21 handling, using a canine model of chronic HF.
The cytosolic Ca21 transients were reduced in amplitude and slowed in duration in HF myocytes compared with control,
changes paralleled by a dramatic reduction in the total SR Ca21 content. Direct measurements of [Ca21]SR in both intact and
permeabilized cardiac myocytes demonstrated that SR luminal [Ca21] is markedly lowered in HF, suggesting that alterations in
Ca21 transport rather than fractional SR volume reduction accounts for the diminished Ca21 release capacity of SR in HF. SR
Ca21 ATPase (SERCA2)-mediated SR Ca21 uptake rate was not signiﬁcantly altered, and Na1/Ca21 exchange activity was
accelerated in HF myocytes. At the same time, SR Ca21 leak, measured directly as a loss of [Ca21]SR after inhibition of
SERCA2 by thapsigargin, was markedly enhanced in HF myocytes. Moreover, the reduced [Ca21]SR in HF myocytes could be
nearly completely restored by the RyR2 channel blocker ruthenium red. The effects of HF on cytosolic and SR luminal Ca21
signals could be reasonably well mimicked by the RyR2 channel agonist caffeine. Taken together, these results suggest that
RyR2-mediated SR Ca21 leak is a major factor in the abnormal intracellular Ca21 handling that critically contributes to the
reduced SR Ca21 content of failing cardiomyocytes.
INTRODUCTION
In cardiac muscle, contraction and relaxation are controlled
by the sarcoplasmic reticulum (SR), a Ca21 storage and
release organelle equipped with specialized molecules to
pump Ca21 into and release Ca21 out of the SR lumen,
namely the SR Ca21 ATPase (SERCA2) and the ryanodine
receptor (RyR2) channel, respectively (1). Contraction is
triggered when a small amount of Ca21 enters the myocyte
via voltage-dependent Ca21 channels and is ampliﬁed by
Ca21-induced Ca21 release (CICR) (2) from the SR through
RyR2s, causing activation of the myoﬁlaments. After CICR,
Ca21 release robustly terminates and enters a refractory state,
processes that are governed by the decline in intra-SR [Ca21]
that accompanies SR Ca21 release (3–5). Once the RyR2
channels close, Ca21 can be effectively pumped back to the
SR by SERCA2, contributing to cardiac relaxation. Al-
though most of the Ca21 constituting the cytosolic Ca21
transient is taken up by the SR, some Ca21 is extruded from
the cell by the Na/Ca21 exchanger (NCX) to balance that
which entered via the Ca21 channels in the plasmalemma. Of
note, Ca21 release channels do not remain completely
quiescent in diastole but instead mediate a measurable SR
Ca21 leak that increases as a function of [Ca21]SR, and limits
the SR Ca21 content (6,7).
Systolic heart failure (HF) is a disease state associated
with weakening of myocardial contractility that ultimately
results in catastrophic deterioration of ventricular pump
function. Although there are many etiologies of HF, reduced
amplitude and prolonged duration of the systolic Ca21
transient are characteristic features of myocytes in HF (8–
10). In most studies, including those in human myocytes,
these HF-associated changes in Ca21 transients are accom-
panied by a decrease in the SR Ca21 content (11–14).
Although it is clear that reduced SR Ca21 content could lead
to reduced systolic Ca21 transients and weakened contrac-
tility, the speciﬁc mechanisms responsible for the reduced
SR Ca21 content in HF remain to be deﬁned. In a number of
studies, evidence from protein expression and SERCA2
activity measurements using homogenized tissue prepara-
tions suggests that SERCA2 function is inhibited in HF
(15–17), although not all studies agree (18,19). At the same
time, NCX function/expression is often up-regulated during
HF (12,13,20). Both of these changes are expected to result
in underﬁlled SR Ca21 stores by facilitating Ca21 removal
from the myocyte at the expense of its uptake into the SR.
Additionally, decreased SERCA2 activity could contribute
to the slowed decay kinetics of the Ca21 transient in HF,
potentially affecting diastolic function. An increase in the SR
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Ca21 leak could also contribute to the reduced SR Ca21
content and abnormal Ca21 transients in HF. Although there
is considerable disagreement regarding the speciﬁc mecha-
nisms governing SR Ca21 leak during HF (21–23), mount-
ing evidence suggests that the RyR2s become functionally
hyperactive, rendering the SR membrane much leakier for
Ca21 compared with controls (24,25). Strikingly, mutations
in RyR2 (or its auxillary proteins) that result in increased SR
Ca21 leak are commonly associated with catecholaminergic
polymorphic ventricular tachycardia rather than HF (26,27).
Therefore, the speciﬁc role of the increased SR Ca21 leak in
abnormal Ca21 handling, and in particular to the reduction
of [Ca21]SR in HF, has yet to be experimentally deﬁned.
Using a canine chronic model of HF, we recently showed
that the RyR2 channel becomes excessively active, resulting
in leaky SR Ca21 stores in HF (25). The increase in RyR2
activity is caused by defective modulation of the channel by
intra-SR luminal Ca21, a mechanism that normally operates
to terminate SR Ca21 release and keep the RyR2 channels
closed (i.e., refractory) during diastole. The goal of this study
was to determine the contribution of elevated SR Ca21 leak
in HF-related alterations in Ca21 handling relative to the
contributions of potential changes in SERCA2 and NCX
activities. To this end, we examined intracellular Ca21 cy-
cling by monitoring Ca21 changes in both the extra- and
intra-SR compartments in intact and permeabilized myocytes
from normal and failing hearts as well as in normal cells
exposed to various concentrations of the RyR2 agonist
caffeine. Our studies show that enhanced SR Ca21 leak via
RyR2s is a primary factor in abnormal intracellular Ca21
handling during heart failure and a critical mediator of
reduced SR Ca21 content in failing cardiomyocytes.
MATERIALS AND METHODS
All animal procedures were approved by The Ohio State University
Institutional Animal Care and Use Committee. Mongrel dogs had HF in-
duced by RV tachypacing for $4.5 months, using a previously described
protocol (28). Cardiac structure and function of control and HF dogs were
analyzed using electrocardiography and echocardiography. Left ventricular
fractional shorteningwas 41.06 1.6% for 8 control dogs and 14.36 1.0% for
11 HF dogs. Myocytes were isolated using previously described techniques
(25) from the midmyocardium of the left ventricular lateral free wall.
Whole-cell patch clamp recordings of transmembrane ionic currents were
performed with an Axopatch 200B ampliﬁer (Axon Instruments, MDS,
Sunnyvale, CA). The external solution contained (in mM): 140 NaCl, 5.4
CsCl, 2.0 CaCl2, 0.5 MgCl2, 10 Hepes, and 5.6 glucose (pH 7.4). Patch
pipettes were ﬁlled with a solution that contained (in mM): 123.4 CsCl, 20
TEACl, 5 MgATP, 5 NaCl, 1 MgCl2, 0.1 Tris GTP, 10 Hepes, and 0.1
Rhod-2 or Fluo-3 K-salt (pH 7.2). Electrical ﬁeld stimulation experiments
were performed using the following external solution (in mM): 140 NaCl,
5.4 KCl, 5.0 CaCl2, 0.5 MgCl2, 10 Hepes, and 5.6 glucose (pH 7.4).
Intracellular Ca21 imaging was performed using Olympus Fluoview
1000 confocal microscope in line-scan or XYmode. To monitor the intra-SR
Ca21 levels, myocytes were loaded with 10 mM Fluo-5N AM for 3–6 h at
37C. Cytosolic Ca21measurements were performed using either Rhod-2 or
Fluo-3 Ca21 indicators. When measured simultaneously, Fluo-5N and
Rhod-2 were excited by 488- and 543-nm laser lines, and ﬂuorescence was
acquired at wavelengths of 500–530 and.590 nm, respectively. Fluo-3 was
excited by the 488-nm line of an argon-ion laser, and the ﬂuorescence was
acquired at wavelengths .510 nm. To avoid movement artifacts, contrac-
tion was suppressed by either 40 mM cytochalasin D (for the experiments
shown in Fig. 1) or 10 mM 2,3-butanedione monoxime (BDM) for the
experiments shown in Fig. 6.
Intra-SR Ca21 dynamics in Fluo-5N-loaded saponin-permeabilized myo-
cytes were studied using an intracellular solution that contained (mM): 120
potassium aspartate, 20 KCl, 3 MgATP, 10 phosphocreatine, 5 U ml1
creatine phosphokinase, 0.5 EGTA (pCa 7), and 20 HEPES (pH 7.2).
For quantitative studies, the temporal dynamics in ﬂuorescence was
expressed as DFCAFF/DFMAX ¼ (F – FCAFF)/(FMAX  FCAFF), where F
represents ﬂuorescence at time t, FCAFF represents the ﬂuorescence level of
the cells after the application of 10 mM caffeine, and FMAX represents Fluo-
5N ﬂuorescence in the presence of 10 mM [Ca21]. In permeabilized
myocytes FMAX was determined by application of 10 mM [Ca
21] in the
presence of 10 mM BDM and 1 mM ionomycin. In intact cells, FMAX was
measured by application of 10 mM [Ca21] in the presence of 10 mM BDM,
1 mM ionomycin, and 0.1% saponin. The amplitude of SR Ca21 depletion
during electrical ﬁeld stimulation was expressed as DF/DFMAX¼(F – F0)/
(FMAX  FCAFF), where F represents nadir ﬂuorescence and F0 stands for
baseline ﬂuorescence. We previously determined that Fluo-5N ﬂuorescence
in the presence of 100mMCa21was quenched by,10% by 10 mM caffeine
(29). Therefore, in this study Fluo-5N ﬂuorescence was not corrected for
caffeine quenching.
Results are mean6 SE, with n representing the number of different cells
used. Statistical signiﬁcance was evaluated either by Student’s t-test or
by ANOVA and t-test with Bonferroni correction, respectively. A value of
p , 0.05 was considered signiﬁcant.
RESULTS
Cytosolic and intra-SR [Ca21]
Wemonitored intracellular Ca21 cycling in intact control and
HF myocytes by simultaneous imaging of [Ca21] changes in
the cytosolic and SR compartments using the Ca21 indicators
Rhod-2 and Fluo-5N, respectively. Representative recordings
of cytosolic and intra-SR [Ca21] changes in control and HF
myocytes during ﬁeld stimulation at 0.5 Hz are shown in
panel A of Fig. 1, whereas panels B–D show averaged data on
the amplitude characteristics of the cytosolic and luminal
Ca21 signals. Electrical stimulation elicited cytosolic Ca21
transients associated with reciprocal dips in [Ca21]SR. The
peak amplitude of cytosolic Ca21 transients was signiﬁcantly
reduced in HF myocytes compared with controls (Fig. 1 B),
consistent with previous studies (13,15,25,30). At the same
time, our [Ca21]SR measurements demonstrated, for the ﬁrst
time, that both the baseline (i.e., diastolic) [Ca21]SR and the
extent of luminal [Ca21] depletion during systolic Ca21
release are dramatically reduced in HF myocytes (Fig. 1, C
and D). These results are consistent with, and signiﬁcantly
extend, previous studies reporting changes in the total SR
Ca21 content as assessed by caffeine-induced Ca21 release
in HF (11–14).
To learn more about the state of SR Ca21 uptake/retention
capacity in HF versus control myocytes, we examined the
kinetics of both cytosolic and intra-SR Ca21 transients. The
time course of decline of the cytosolic Ca21 transients was
characteristically slowed in HF myocytes with respect to
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controls (Fig. 2, A and B). On average, the rate of Ca21
transient decay was slowed by 36% in HF myocytes (Table
1). In addition to a reduction in Ca21 sequestration, this
alteration could be attributable to potential changes in Ca21
transport across the sarcolemma such as slowed Ca21
extrusion or increased Ca21 entry on either the forward- or
reverse-mode NCX, respectively. The time course of the
[Ca21]SR signal after SR Ca
21 release provides a more im-
mediate measure of SR Ca21 resequestration than the decay
of the cytosolic Ca21 transient. As demonstrated in Fig. 2 (A,
lower panel, and C), the rate of [Ca21]SR recovery after
release was slower by 32% in HF myocytes than in controls
(p , 0.05) (see also Table 1). These results suggest that the
ability of SR to resequester (i.e., take up and retain) Ca21 is
impaired in HF myocytes.
NCX activity
We obtained an estimate of intrinsic NCX-mediated Ca21
extrusion activity in control versus HF myocytes by mea-
suring the rate of cytosolic Ca21 decline during Ca21 tran-
sients induced by caffeine. Fig. 3 provides representative
traces of Ca21 transients elicited by 10 mM caffeine (panel A)
and pooled data for the amplitude and decay time constants of
caffeine-induced Ca21 transients in control and HF myocytes
(panels B and C, respectively). The amplitude of the caffeine-
induced Ca21 transients was reduced, consistent with the
measurements of [Ca21]SR above. The rate of decay of caffeine-
induced Ca21 transients showed 31% acceleration in HF
myocytes, suggesting an increase in NCX Ca21 extrusion
activity (Table 1). Enhanced Ca21 extrusion via NCX could,
to some extent, contribute to the reduced [Ca21]SR in HFmyo-
cytes. However, this inﬂuence is likely to be minor consid-
ering that the rate of Ca21 extrusion via NCX is severalfold
slower than the rate of Ca21 resequestration into SR (Table 1).
SERCA2-mediated Ca21 uptake
The ability of the SR to take up and retain Ca21 is deter-
mined by two competing processes: SERCA2-mediated
transport of Ca21 to the SR lumen and Ca21 leak through
RyR2s. To assess the relative roles of these mechanisms in
the HF-related decrease of SR net Ca21 sequestration
capacity, we performed direct measurements of SERCA2-
mediated Ca21 uptake in saponin-permeabilized myocytes in
the presence the RyR2 antagonist ruthenium red (Rut Red).
In these experiments, the SR was ﬁrst depleted in a Ca21-free
solution using caffeine (10 mM). Then SR Ca21 uptake was
initiated by addition of either 100 or 500 nM Ca21 to the
bathing solution and tracked by measuring the elevation of
[Ca21]SR with Fluo-5N. Representative traces of SR Ca
21
uptake along with the experimental protocol are shown in
Fig. 4 A, whereas Fig. 4 B presents pooled data on the time
constants of SR Ca21 uptake in control and HF myocytes. In
HF myocytes, the time constants of SR Ca21 uptake were not
signiﬁcantly different (p. 0.5) from those measured in con-
trol myocytes. Thus, the intrinsic Ca21 uptake activity of
SERCA2 appears to be unchanged in HF myocytes.
FIGURE 1 Simultaneous measure-
ments of cytosolic and intra-SR [Ca21]
transients. (A) Representative line-scan
images of Rhod-2 (upper) and Fluo-5N
(lower) ﬂuorescence in control (C)
and heart failure (HF) myocytes. Ca21
transients were evoked by 0.5-Hz
electrical ﬁeld stimulation. (B) Average
amplitudes (F/F0) of cytosolic Ca
21
transients were 2.21 6 0.12 in control
(C) and 1.44 6 0.06 in HF myocytes.
(C) Average amplitudes (DF/DFMAX)
of SR Ca21 depletion were 0.146 0.04
in control (C) and 0.04 6 0.007 in HF
myocytes. (D) The average levels of
free diastolic SR Ca21 (DFCAF/DFMAX)
in control (C) and HF myocytes were
0.53 6 0.07 and 0.39 6 0.02, respec-
tively (*p , 0.05; **p , 0.01 versus
controls).
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SR Ca21 leak
We directly measured the rate of SR Ca21 leak by moni-
toring the time-dependent decline of [Ca21]SR in permeabi-
lized myocytes, after inhibition of SERCA2 by thapsigargin
(Fig. 5 A). At steady state, [Ca21]SR is determined by the
balance between SERCA2-mediated Ca21 uptake and Ca21
leak through RyR2s. Similar to the results in intact cells
(Fig. 1 D), the baseline [Ca21]SR was dramatically lowered
in permeabilized myoyctes in the HF group compared with
controls. Inhibition of SERCA2 resulted in a decline of
[Ca21]SR in both control and HF myocytes with slopes
proportional to Ca21 leak rates. Consistent with a predom-
inant role of Ca21 leak in HF-related reduction of [Ca21]SR,
the SR Ca21 leak rate was markedly enhanced in HF
myocytes compared with controls (Fig. 5, A and B, and see
Fig. 7 B). To ensure that the increased Ca21 leak observed in
HF myocytes was not caused by nonlinear properties of
Fluo-5N, the kinetics of [Ca21]SR decline in the presence of
thapsigargin was analyzed over the same range of Fluo-5N
signal in both control and HF myocytes (Fig. 5 B).
To further assess the role of enhanced RyR2-mediated
Ca21 leak in HF-related [Ca21]SR reduction, we investigated
the relative effects of Rut Red on [Ca21]SR in permeabilized
control and HF myocytes (Fig. 5 C). Application of 10 mM
Rut Red produced a modest increase in [Ca21]SR in control
myocytes, indicative of a basal SR Ca21 leak occurring via
RYR2s. In HF myocytes the effect of Rut Red on [Ca21]SR
was substantially greater, suggesting that RyR2-mediated SR
Ca21 leak plays a signiﬁcant role in mediating the decrease
in [Ca21]SR in HF. However, it is to be noted that Rut Red
did not raise [Ca21]SR completely to the level of [Ca
21]SR
seen in control myocytes (Fig. 5, C and D). This could
indicate either a lower efﬁcacy of Rut Red as a RyR2 inhib-
itor in HF myocytes exhibiting a greater RyR2-mediated SR
FIGURE 2 HF slows the kinetics of cytosolic and SR Ca21 transients. (A)
Representative time-dependent proﬁles of cytosolic (upper panel) and intra-
SR (lower panel) Ca21 transients induced by 0.5-Hz electrical ﬁeld
stimulation in control (C) and HF myocytes. The decay of the transients was
ﬁt by a single exponential function with speciﬁed time constants. Insets
show Ca21 transients with normalized amplitudes. (B) Average time
constants of cytosolic Ca21 transient decays were 295 6 24 ms in control
(C) and 4476 32 ms in HF myocytes. (C) Average time constants of the SR
Ca21 transient decays were 3076 26 ms in control (C) and 4416 26 ms in
HF myocytes (*p , 0.05; **p , 0.01).
TABLE 1 Rate constants of Ca21 transients in control (C)
and heart failure (HF) myocytes
Rates Control n Heart failure n HF/C
Rate twitch, s1 3.6 6 0.3 11 2.3 6 0.2 10 64%
Rate NCX, s1 0.39 6 0.03 9 0.51 6 0.04 9 131%
Rate SR*, s1 3.4 6 0.3 7 2.3 6 0.1 8 68%
*Deﬁned from the kinetics of [Ca21]SR depletion signal; n ¼ number of
cells studied.
FIGURE 3 HF reduces SR Ca21 content and moderately increases the
rate of cytosolic Ca21 removal by NCX. (A) Representative recordings of
Ca21 transients induced by rapid application of 10 mM caffeine in control
(C) and HF myocytes. The inset shows caffeine-induced Ca21 transients
with normalized amplitude. (B) Average amplitudes (F/F0) of caffeine-
induced Ca21 transients were 6.146 0.47 in control and 4.696 0.30 in HF
myocytes, respectively. (C) The decay time constants of the caffeine-
induced Ca21 transients in control and HF myocytes were 2.8 6 0.3 and
2.0 6 0.1 s, respectively (*p , 0.05).
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Ca21 leak or the existence of a Ca21 leak component
mediated by a pathway(s) other then the RyR2s such as
inositol trisphosphate receptors (IP3Rs) the expression of
which is increased in HF (31).
Comparison with the effects of caffeine
To further examine whether, and to what extent, HF-related
changes in Ca21 cycling could be attributed to a Ca21 leak
via RyR2s, we investigated changes in cellular Ca21 cycling
caused by the RyR2 agonist caffeine in normal myocytes.
Fig. 6 shows representative traces of cytosolic and SR
luminal Ca21 concentrations in a voltage-clamped myocyte
stimulated at 0.5 Hz before and after exposure to two
different concentrations of caffeine (3 and 6 mM). Caffeine
decreased the amplitude and prolonged the duration of Ca21
transients. At the same time, caffeine led to a decrease in
both basal and systolic [Ca21]SR. These effects of caffeine
were concentration dependent with higher caffeine doses
causing more profound changes. The HF-related changes in
cytosolic and luminal Ca21 signals could be approximately
emulated by 3 mM caffeine. Similar results were obtained in
four other myocytes.
The application of caffeine reproduced the leaky SR
phenotype in permeabilized control myocytes. As shown in
Fig. 7, A and C, application of low doses of caffeine to a
normal myocyte induced a reduction in [Ca21]SR similar to
that observed in HF myocytes, and the application of
thapsigargin produced a Ca21 leak with a rate comparable,
albeit somewhat faster than, that in HF myocytes. Pooled
data on the rate of SR Ca21 leak recorded in the presence of
1 mM caffeine in comparison with basal leak rates measured
in control and HF myocyes are presented in Fig. 7 B. The
effects of two incremental additions of caffeine (0.5 and
2 mM) on basal [Ca21]SR are documented in Fig. 7 C. Again,
application of 0.5 mM of caffeine lowered [Ca21]SR to a
level corresponding to that in HF, and the higher dose
induced a larger although still incomplete depletion of
[Ca21]SR as revealed by addition of 10 mM at the end of the
experiment. Importantly, Rut Red added in the presence of
1 mM caffeine failed to elevate [Ca21]SR to the level attained
with the same dose of Rut Red in the absence of caffeine
(Fig. 7, C and D). Reminiscent of the experiments in HF
myocytes, these results suggest that inhibition of RyR2s by
Rut Red is incomplete at the concentration used (10 mM) or
that the inhibition can be overcome by caffeine. Collectively,
these results suggest that the HF-related changes in cellular
Ca21 handling can be reproduced reasonably well in control
myocytes with caffeine at concentrations of 0.5–3 mM, de-
pending on experimental settings.
DISCUSSION
In this study, we investigated the role of elevated SR Ca21
leak through RyR2s in HF-related abnormalities of intracel-
lular Ca21 handling, using a canine model of chronic HF.
Our study shows for the ﬁrst time that the increase in the
RyR2-mediated Ca21 leak is a major factor in the reduced
SR Ca21 content and the decreased amplitude and slowed
time course of cytosolic Ca21 transients in cardiac myocytes
from failing hearts.
Role of enhanced SR Ca21 leak in abnormal
Ca21 handling in HF
Consistent with previous studies (13,15,25,30), the cytosolic
Ca21 transients were markedly reduced in amplitude and
slowed in duration in HF myocytes compared with control
myocytes, changes paralleled by a signiﬁcant reduction in
the total SR Ca21 content. These alterations in Ca21
handling are considered to be hallmarks of HF (8–10). The
HF-induced reduction of the size of the functional Ca21 store
could be caused either by a potential decrease in SR volume
(per-myocyte volume) or by a reduction of [Ca21] in the
lumen of SR in HF myocytes (32). Our direct measurements
of [Ca21]SR in both intact and permeabilized cardiac cells
demonstrated that SR luminal [Ca21] is manifestly lowered
in HF myocytes, suggesting that alterations in Ca21 transport
rather than fractional SR volume contraction accounts for the
FIGURE 4 SERCA2-mediated SR Ca21 uptake is not signiﬁcantly
altered in HF myocytes. (A) Time course of SR Ca21 uptake in control
and HF permeabilized myocytes, measured with Fluo-5N-loaded SR, in the
presence of 10 mM ruthenium red (Rut Red). The SR [Ca21] was depleted
with 10 mM caffeine in Ca21-free solution, and SR Ca21 uptake was ini-
tiated by the addition of either 100 or 500 nM of Ca21. (B) Average time
constants (from exponential ﬁt) of SR Ca21 uptake were 45.5 6 3.1 s in
control (C) and 48.96 2.4 s in HFmyocytes, when measured in the presence
of 100 nM Ca21, and 12.0 6 0.7 s in control and 10.5 6 0.6 s in HF
myocytes, when measured in the presence of 500 nM Ca21.
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diminished Ca21 release capacity of SR in HF. Potential
contributors to the decreased [Ca21]SR in HF include reduced
SR Ca21-ATPase function, enhanced NCX Ca21 extrusion
activity, and/or increased SR Ca21 leak. Based on our exper-
iments, SR Ca21 uptake rate was not signiﬁcantly altered in
HF myocytes. This lack of functional changes is consistent
with the unchanged levels of SERCA2a expressed in failing
myocytes using this particular model of HF (25). Although
NCX activity was accelerated in HF myocytes, these changes
in NCX function were relatively modest (;30%) and could
not account for the altered Ca21 transients in HF myocytes.
Indeed, we found that HF myocytes exhibited a similar
reduction in [Ca21]SR regardless of whether they were intact
or permeabilized (Fig. 1, A and D, and Fig. 5, C and D),
suggesting that NCX is not a major contributor to the reduced
[Ca21]SR in HF under our experimental conditions. At the
same time, SR Ca21 leak, measured directly as a reduction in
[Ca21]SR after inhibition of SERCA2 by thapsigargin, was
markedly enhanced in HF myocytes. Moreover, the reduced
[Ca21]SR in HF myocytes could be nearly completely
restored by the RyR2 channel blocker Rut Red. Thus, based
on our experiments, enhanced SRCa21 leak is a critical factor
determining the reduced [Ca21]SR in HF with altered
SERCA2- and NCX-mediated Ca21 transport playing no
major role in modulating [Ca21]SR.
Importantly, the increased SR Ca21 leak not only contrib-
uted to the reduced SR Ca21 content but also inﬂuenced the
dynamics of resequestration of Ca21 into the SR and was also
likely to be responsible for the slowed kinetics of the cytosolic
Ca21 transients in HF myocytes. Indeed, the kinetics of
recovery of both [Ca21]SR and cytosolic Ca
21 signals after
each release was slowed in HF myocytes despite the fact that
SERCA2 and NCX activities exhibited either no change or
were increased, respectively, in HF myocytes. Our ﬁndings
are consistent with those of Litwin et al. (33), which showed
that sustained SR Ca21 release rather than inhibition of SR
Ca21 uptake accounts for the slowed kinetics of the cytosolic
Ca21 transients in myocytes from infarcted rabbits. These
results along with those obtained with caffeine (see below)
suggest that caution must be exercised when using kinetics of
Ca21 transient decay as ameasure of SERCA2Ca21 transport
activity, especially in disease states where SR Ca21 leak can
profoundly affect the Ca21 transient time course.
Effects of caffeine
The effects of HF on cytosolic and SR luminal Ca21 signals
could be reasonably well mimicked by the RyR2 channel
agonist caffeine, further supporting the notion that Ca21 leak
via RyR2s is a major contributor to the HF-related changes in
FIGURE 5 HF increases SR Ca21 leak. (A) Time-
dependent proﬁles of intra-SR Ca21 signals. Application
of 10 mM of thapsigargin (Tg) evokes a steady loss of
intra-SR Ca21, visualized by the decline of the Fluo-5N
signal, which was signiﬁcantly faster in permeabilized
myocytes from failing hearts. Then 10 mM caffeine (Caf)
was applied to determine the Fluo-5N signal with depleted
SR. Maximal Fluo-5N signal was determined by simulta-
neous application of 1 mM ionomycin with 10 mM Ca21
and 10 mM BDM. (B) Time course of normalized Fluo-5N
signals in control and HF myocytes measured in the
presence of Tg, as demonstrated in panel A. Kinetic
analysis was performed in both control and HF over the
same range of Fluo-5N signal, as indicated in panel A by
the wide black line. Dotted lines represent exponential ﬁt to
the data. (C) Time-dependent proﬁles of intra-SR Fluo-5N
signals before and after application of 10 mM ruthenium
red (Rut Red) in control and HF cells. (D) In control
myocytes, normalized [Ca21]SR levels were 0.836 0.02 in
the absence of, and 0.92 6 0.02 in the presence of, Rut
Red, respectively. In HF myocytes, normalized [Ca21]SR
levels were 0.616 0.03 in the absence of, and 0.776 0.04
in the presence of, Rut Red, respectively (*p, 0.05 versus
control; **p , 0.01 versus control).
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myocyte Ca21 handing. Similar to the HF phenotype, caf-
feine at intermediate to high concentrations reduced the am-
plitude and slowed the time course of cytosolic Ca21
transients and increased baseline (diastolic) [Ca21]cyt in
control cells. The inhibitory effects of intermediate and high
concentrations of caffeine on the amplitude and rate of decay
of the cytosolic Ca21 transient are consistent with previous
studies (34). Caffeine also reduced both the diastolic and
systolic [Ca21]SR and slowed the recovery rate of [Ca
21]SR
after Ca21 release. The HF-induced changes in the param-
eters of cytosolic and luminal Ca21 signals could be approxi-
mately matched with the addition of 0.5–3 mM caffeine,
permitting us to ‘‘calibrate’’ the impact of HF on SR Ca21
leak in terms of effects of a well-studied RyR opener.
Considerations of Ca21 homeostasis
Based on studies using low concentrations of the RyR2
channel modulators caffeine and tetracaine, it has been
shown (35) that the SR Ca21 release mechanism in cardiac
myocytes possesses a capacity for self-regulation, which
allows myocytes to maintain Ca21 transients of constant am-
plitude in the face of interventions that alter RyR2 activity.
Thus, a reduction in Ca21 transient amplitude by such an
intervention would result in both reduced Ca21 extrusion via
NCX and reduced Ca21-dependent inactivation of ICa and,
hence, increased retention of Ca21 in the myocyte, which
would contribute to the Ca21 transient during the next Ca21
release cycle. Therefore, one might expect that the RyR2-
mediated leak in HF would lead only to a transient change in
the amplitude of cytosolic Ca21 transients without producing
steady-state inhibitory (or potentiatory) effects on cytosolic
Ca21 transients. However, as we demonstrated by the appli-
cation of moderate to high doses of caffeine, the ability of
the SR to preserve normal Ca21 release amplitude depends
on the extent to which the RyR2 function is altered. When
the RyR2 becomes excessively active, the SR loses its ca-
pacity to retain Ca21 during diastole, resulting in a partial or
even complete elimination of the SR Ca21 store. Because the
majority of Ca21 contributing to the Ca21 transient comes
from the SR, this unavoidably leads to reduced Ca21 tran-
sients as is manifested in HF myocytes.
Mechanisms for enhanced RyR2 activity
The speciﬁc biochemical defect(s) causing RyR2 to become
leaky in HF is not known. It has been proposed that RyR2
phosphorylation either by PKA or CAMKII may contribute
to the SR leak in HF by rendering RyR2s hyperactive
(21,36–39). Alternatively, enhanced RyR2 activity could be
caused by modiﬁcation of the channel protein by reactive
oxygen or reactive nitrogen species generated in HF (40,41).
Recently, using the same canine model, we demonstrated
that the enhanced RyR2 activity in HF is caused by
sensitization of the RyR2 to activation by luminal Ca21
(25). This ﬁnding explains why SR Ca21 leak is high despite
the reduced SR luminal Ca21 levels in HF myocytes,
considering the well-known positive relationship between
SR Ca21 load and RyR2 activity (42). Consistent with this
mechanism, our direct measurements of [Ca21]SR showed
that Ca21 release terminates at much lower [Ca21]SR in HF
myocytes compared with normal myocytes, indicative of an
extended range of Ca21 concentrations enhancing RyR2
channel activity in HF. It remains to be seen whether these
changes in RyR2 function are also modulated by changes in
RyR2 phosphorylation or redox modulation. Because regu-
lation of RyR2s by luminal Ca21 may involve RyR2’s
luminal binding partners, including calsequestrin, triadin,
and junctin (43,44), it is also conceivable that alterations in
interactions of RyR2 with these proteins contribute to
abnormal RyR2 channel function in HF. Although the levels
of these proteins are not changed, RyR2 expression is mark-
edly reduced in this model of HF (25). Because both triadin
and junctin appear to increase RyR2 activity (44), an in-
creased ratio of triadin and junctin to RyR2 could contribute
FIGURE 6 Caffeine mimics the properties of global Ca21 release
observed in HF. Representative simultaneous recordings of cytosolic
(measured with Rhod-2) and intra-SR [Ca21] (measured with Fluo-5N)
signals in voltage-clamped myocytes before and after application of the
speciﬁed concentrations of caffeine. Caffeine produced signiﬁcant deceler-
ation of relaxation and decreased amplitudes of the cytosolic and intra-SR
[Ca21] transients. Ca21 transients were evoked by 300-ms depolarizing
steps from a holding potential of 50 mV to 0 mV every 2 s.
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to increased RyR2 function in HF. Additionally, CASQ2
glycosylation is dramatically altered in HF, indicative of
defective junctional SR trafﬁcking and Ca21 release com-
plex assembly (45).
Comparison with previous studies
Our results corroborate previous studies that demonstrated
that an elevated SR Ca21 leak exists in myocytes from
failing hearts using rabbit and dog HF models (24,25).
Moreover, our data show that enhanced SR Ca21 leak can be
a primary determinant of altered Ca21 handling in HF
myocytes. At this time it is unclear whether the prevailing
role of SR Ca21 leak and the apparent lack of effects on SR
Ca21 uptake are speciﬁc features of this particular disease
model or are more general properties of HF. The contribution
of SR Ca21 leak to HF-related alterations in SR function may
vary among different models and stages of HF and is difﬁcult
to quantify because of the presence of competing Ca21
ﬂuxes, including those mediated by SERCA2 and NCX.
Application of approaches developed in this study to other
models and stages of HF should certainly clarify this issue.
Using a shorter-term (3–6 weeks) canine model of
tachypacing-induced HF, Hobai and O’Rourke (13) showed
that reduced SR Ca21 content is responsible for depressed
SR Ca21 release in HF. Although potential changes in
SERCA2 function and SR Ca21 leak were not estimated in
that study, the marked prolongation of the Ca21 transient
decay indicates that either the uptake or retention of Ca21 by
the SR, or both, were affected through potential inhibition of
SERCA2 and/or stimulation of SR Ca21 leak. At the same
time, NCX Ca21 extrusion activity was enhanced by 50%
and was also likely to be contributing to the reduced SR
Ca21 content. A study using a rabbit model of HF found
a substantial SR Ca21 leak (24), but its signiﬁcance was
deemed secondary to enhanced NCX-mediated Ca21 extru-
sion in view of the marked up-regulation of NCX activity in
this model. In human HF, NCX was shown to change little,
and alterations in Ca21 handling were ascribed to the
reduced Ca21 uptake capacity of the SR, manifested as
slowed Ca21 transient decay (14). Because the slowed
kinetics of the Ca21 transient could be attributable to both
slowed SERCA2-mediated Ca21 uptake and increased SR
Ca21 leak, it is possible that in human HF, increased SR
Ca21 leak is an important factor in acquisition of the HF-
related Ca21 transient phenotype, as we show in our chronic
canine model of HF. Although it demonstrates the impor-
tance of a SR Ca21 leak, our study does not rule out other
potential mechanisms, including failure of SR Ca21 release
activation caused by structural changes (46) or alterations in
myocyte electrical excitability (47), contributing to defective
Ca21 signaling in the failing heart.
CONCLUSION
In conclusion, this study used a large animal model of
chronic heart failure, closely relevant to human disease, to
demonstrate that elevated Ca21 leak from the SR via RyR2s
can be a major factor in determining the altered properties of
cytosolic Ca21 transients in HF. Our ﬁndings support the
notion that targeting the RyR2 might be a logical therapeutic
approach to treating HF (48). However, implementing a
successful therapy based on RyR2 targeting could be chal-
lenging, considering the complex nature of store-mediated
Ca21 signaling. Indeed, inhibition of RyR2s may ﬁx the leak
but at the same time impair systolic function. Establishing
FIGURE 7 Caffeine application to control myocytes
mimics the properties of the SR Ca21 leak observed in HF
myocytes. (A) Time-dependent proﬁles of intra-SR Ca21
signals. Application of 10 mM thapsigargin (Tg) evokes a
steady loss of intra-SR Ca21, visualized by the decline of
Fluo-5N signal. Caffeine (1 mM) produces SR Ca21 leak
acceleration that is qualitatively similar to that occurring in
HF. Dotted lines represent time-dependent proﬁles of intra-
SR Ca21 signals recorded in control (black) and HF (gray)
myocytes. (B) Decline of Fluo-5N signal in the presence of
thapsigargin was ﬁt by an exponential function. The
average time constants were 713 6 160, 337 6 53, and
201 6 27 s in controls, HF myocytes, and control
myocytes in the presence of 1 mM caffeine, respectively.
(C) Time-dependent proﬁles of intra-SR Fluo-5N signals
in control cells before and after application of 10 mM
ruthenium red (Rut Red) in the absence and in the presence
of speciﬁed concentrations of caffeine. Caffeine (Caf, 10
mM) was applied to determine Fluo-5N signal with Ca21-
depleted SR. The maximal Fluo-5N signal was determined
by simultaneous application of ionomycin with 10 mM
Ca21 and 10 mM BDM. In the absence of caffeine, normalized [Ca21]SR levels were 0.73 6 0.03 before and 0.92 6 0.03 during application of Rut Red,
respectively. In the presence of 2 mM caffeine, normalized [Ca21]SR levels were 0.28 6 0.03 before and 0.76 6 0.03 during the application of Rut Red,
respectively (*p , 0.05 versus control; **p , 0.01 versus control).
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the precise molecular mechanism(s) responsible for HF-
related abnormalities in RyR2s should facilitate the devel-
opment of a rational strategy to normalize Ca21 cycling and
myocardial performance in HF.
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